Literature DB >> 12973819

Average bioequivalence of generic clarithromycin tablets in healthy Thai male volunteers.

Ornrat Lohitnavy1, Manupat Lohitnavy, Kannika Sareekan, Sanglar Polnok, Prawit Taytiwat.   

Abstract

The objective of this study was to assess bioequivalence of 500-mg clarithromycin tablets in 24 healthy volunteers. In a randomized, single dose, fasting state, two-period, crossover study design with a 1-week washout period, each subject received a 500-mg clarithromycin tablet. Plasma samples were collected over a 24-h period after administration and were analyzed by using a validated method using high performance liquid chromatography (HPLC) with electrochemical detection. The time to reach the maximal concentration (t(max),h), the peak concentration (C(max),ng/ml) and the area under the curve (AUC(0- infinity),ng h/ml) of the Reference and Test formulations were 2.1+/-0.7 vs 2.1+/-0.7, 2474+/-702 vs 2559+/-744 and 15803+/-6120 vs 17683+/-6650, respectively. Relative bioavailability was 1.12. The 90% confidence interval (90% CI) of C(max) and AUC(0- infinity) were 95.6-110.8% and 3.5-122.0%, respectively. Bioequivalence between the test and reference preparation can be concluded. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12973819     DOI: 10.1002/bdd.341

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  3 in total

1.  A survey of the quality of generic clarithromycin products from 18 countries.

Authors:  C H Nightingale
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 2.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

3.  Comparison of microbiological and high-performance liquid chromatographic methods for determination of clarithromycin levels in plasma.

Authors:  Farzaneh Lotfipour; Hadi Valizadeh; Somayeh Hallaj-Nezhadi; Morteza Milani; Parvin Zakeri-Milani
Journal:  Iran J Pharm Res       Date:  2010       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.